Sarepta Therapeutics (SRPT) Assets Average (2011 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Assets Average of $3.3 billion for Q1 2026, down 12.11% year-over-year from $3.7 billion in Q1 2025, and down 4.6% quarter-over-quarter from $3.4 billion in Q4 2025.
Sarepta Therapeutics (SRPT) Assets Average (2011 - 2026) Analysis & Trends
Sarepta Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $3.3 billion for Q1 2026.
- In Q1 2026, Assets Average fell 12.11% year-over-year to $3.3 billion; the TTM figure through Mar 2026 stood at $3.3 billion (down 12.11% YoY), while the FY2025 annual figure was $3.7 billion, up 1.18% from the prior year.
- Assets Average for Q1 2026 stood at $3.3 billion, down from $3.4 billion in the prior quarter.
- The five-year high for Assets Average was $3.8 billion in Q4 2024, with the low at $3.0 billion in Q2 2022.
- The 5-year median for Assets Average is $3.2 billion (2024), against an average of $3.3 billion.
- The sharpest annual moves came in 2024 and 2026: Assets Average gained 18.65% in 2024, then retreated 12.11% in 2026.
- Sarepta Therapeutics' Assets Average stood at $3.1 billion in 2022, then increased by 1.43% to $3.2 billion in 2023, then increased by 18.65% to $3.8 billion in 2024, then retreated by 9.52% to $3.4 billion in 2025, then dropped by 4.6% to $3.3 billion in 2026.
- Business Quant data shows SRPT's Assets Average at $3.3 billion in Q1 2026, $3.4 billion in Q4 2025, and $3.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 3.18 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.18 Bn |
| Mar 31, 2026 | 3.26 Bn |
| Dec 31, 2025 | 3.42 Bn |
| Sep 30, 2025 | 3.59 Bn |
| Jun 30, 2025 | 3.57 Bn |
| Mar 31, 2025 | 3.71 Bn |
| Dec 31, 2024 | 3.78 Bn |
| Sep 30, 2024 | 3.51 Bn |
| Jun 30, 2024 | 3.32 Bn |
| Mar 31, 2024 | 3.24 Bn |
| Dec 31, 2023 | 3.19 Bn |
| Sep 30, 2023 | 3.12 Bn |
| Jun 30, 2023 | 3.09 Bn |
| Mar 31, 2023 | 3.09 Bn |
| Dec 31, 2022 | 3.14 Bn |
| Sep 30, 2022 | 3.08 Bn |
| Jun 30, 2022 | 3.03 Bn |
| Mar 31, 2022 | 3.10 Bn |
| Dec 31, 2021 | 2.91 Bn |
| Sep 30, 2021 | 2.71 Bn |